

ARTICLE

LRP5 variants may contribute to ADPKD

Wybrich R Cnossen¹, René HM te Morsche¹, Alexander Hoischen², Christian Gilissen², Hanka Venselaar³, Soufi Mehdi⁴, Carsten Bergmann^{5,6}, Monique Losekoot⁷, Martijn H Breuning⁷, Dorien JM Peters⁸, Joris A Veltman^{2,9} and Joost PH Drenth^{*,1}

Mutations in Polycystic Kidney Disease proteins (*PKD1* or *PKD2*) are causative for autosomal dominant polycystic kidney disease (ADPKD). However, a small subset of ADPKD probands do not harbor a mutation in any of the known genes. Low density lipoprotein Receptor-related Protein 5 (*LRP5*) was recently associated with hepatic cystogenesis in isolated polycystic liver disease (PCLD). Here, we demonstrate that this gene may also have a role in unlinked and sporadic ADPKD patients. In a cohort of 79 unrelated patients with adult-onset ADPKD, we identified a total of four different *LRP5* variants that were predicted to be pathogenic by *in silico* tools. One ADPKD patient has a positive family history for ADPKD and variant *LRP5* c.1680G > T; p.(Trp560Cys) segregated with the disease. Although also two *PKD1* variants probably affecting protein function were identified, luciferase activity assays presented for three *LRP5* variants significant decreased signal activation of canonical Wnt signaling. This study contributes to the genetic spectrum of ADPKD. Introduction of the canonical Wnt signaling pathway provides new avenues for the study of the pathophysiology.

European Journal of Human Genetics (2016) 24, 237–242; doi:10.1038/ejhg.2015.86; published online 29 April 2015

INTRODUCTION

Autosomal dominant polycystic kidney disease (ADPKD; MIM 173900) is the most common renal Mendelian disorder with a global prevalence of 1/400–1/1000.¹ Development of multiple fluid-filled cysts may cause bilateral enlarged kidneys and result in end-stage renal disease. Renal replacement therapy is necessary in about ~5% of ADPKD patients.¹ In addition, the majority of ADPKD patients have health-care issues owing to extrarenal features and complications such as polycystic liver disease (PCLD; 83%), hypertension (80%), cardiac valve abnormalities (25%), intracranial aneurysm (10%) and cysts in the pancreas and other organs.^{2,3}

There is a broad clinical expression of (extra-)renal manifestations and symptoms among ADPKD patients.^{1,3} The phenotype of affected individuals from single large pedigrees may cover the complete spectrum of ADPKD ranging from few renal cysts to grossly enlarged polycystic kidneys with renal failure.⁴ These observations suggest that modifying factors, *in trans* or multiple PKD mutations may influence the onset and course of renal cystogenesis.^{5,6}

The genotype–phenotype correlation is not completely understood in ADPKD.⁷ Linkage studies identified two disease-causing genes, Polycystic Kidney Disease 1 protein (*PKD1*; Chr.16p13.3; NG_008617.1) and Polycystic Kidney Disease 2 protein (*PKD2*; Chr.4q22.1; NG_008604.1).^{8,9} Molecular screening may confirm the clinical diagnosis with a mutation frequency of 76% *PKD1* and 13% *PKD2*.^{10,11} Despite thorough screening, ~11% of families remain unlinked to either locus, which suggest genetic heterogeneity.^{10,11}

Approximately 10% of ADPKD patients have no family history of renal disease.¹² These solitary cases may have mild or severe polycystic kidneys owing to incomplete disease penetrance, *de novo* (modifier) gene variants and environmental influences.

Recently, we identified the Low density lipoprotein Receptor-related Protein 5 (*LRP5*) gene (Chr.11q13.2; NG_015835.1) as the third locus associated with isolated PCLD (PCLD; MIM 174050) by whole-exome sequencing in an extended family.¹³ As PCLD is the most common extra-renal feature in ADPKD patients, we hypothesized that *LRP5* variants may contribute to hepatic and renal disease heterogeneity in ADPKD. We addressed the role of *LRP5* by screening all 23 exons in 79 unlinked and/or sporadic ADPKD patients, and performed some functional analyses.

MATERIALS AND METHODS

Patients

This study was approved by the institutional review board and ethics committee of the Radboud university medical center, Nijmegen. All participants provided informed consent. The families were recruited in The Netherlands, screened according to the Ravine criteria¹⁴ and blood samples were collected.

Polycystic kidney disease mutation analysis

Mutation screening of *PKD1* (NM_001009944.2) and *PKD2* (NM_000297.2) involved Sanger sequencing of exons and flanking intronic regions and multiplex ligation-dependent probe amplification analysis in all probands by using bidirectional Sanger sequencing on ABI3730 Genetic Analyzers (Applied Biosystems, Waltham, MA, USA). *PKD1* variants were assessed using the

¹Department of Gastroenterology and Hepatology, Institute for Genetic & Metabolic Disease (IGMD), Radboud Institute for Molecular LifeSciences (RIMLS), Radboud university medical center, Nijmegen, The Netherlands; ²Department of Human Genetics, Institute for Genetic & Metabolic Disease (IGMD), Radboud Institute for Molecular LifeSciences (RIMLS), Radboud university medical center, Nijmegen, The Netherlands; ³Center for Molecular and Biomolecular Informatics, Institute for Genetic & Metabolic Disease (IGMD), Radboud Institute for Molecular LifeSciences (RIMLS), Radboud university medical center, Nijmegen, The Netherlands; ⁴Department of Gastrointestinal and Oncological Surgery, Faculty of Medicine, University Mohammed First, Oujda, Morocco; ⁵Center for Human Genetics, Bioscientia, Ingelheim, Germany; ⁶Department of Nephrology and Center for Clinical Research, University Hospital Freiburg, Freiburg, Germany; ⁷Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; ⁸Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; ⁹Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands

*Correspondence: Dr JPH Drenth, Department of Gastroenterology and Hepatology, Radboud university medical center, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands. Tel: +31 24 3614760; Fax: +31 24 3540103; E-mail: joostphdrenth@cs.com

Received 20 September 2014; revised 27 February 2015; accepted 27 March 2015; published online 29 April 2015

Autosomal Dominant Polycystic Kidney Disease mutation database v.3.0, <http://pkdb.mayo.edu/>.¹⁵ Protein Kinase C Substrate 80 K-H (*PRKCSH*; NM_002743.3) and SEC63 homolog (*SEC63*; NM_007214.4) were analyzed in two probands with severe polycystic livers (109 from family A and 101 from family D) and patient 102 (family B) was screened for Polycystic Kidney and Hepatic Disease 1 protein (*PKHD1*; NM_138694.3) and Hepatocyte Nuclear Factor-1-beta (*HNF-1 β* ; NM_000458.2).

LRP5 sequencing and *in silico* analysis

All 23 exons of the *LRP5* gene (NM_002335.3) were screened using High Resolution Melting followed by Sanger sequencing. Scoring of *LRP5* variants was performed with homology modeling, *in silico* analysis such as PolyPhen2, Mutpred, SIFT, Align GVGD, PhyloP and the Grantham score. Genome-wide sequence data from the 1000 Genomes Project, 6500 individuals from the National Heart, Lung and Blood Institute Exome Sequencing Project (version 0.0.27), ~500 individuals from the Genome of The Netherlands, exome data from ~2000 individuals of predominantly European ancestry sequenced in-house, and DNA samples from 525 Moroccan healthy, unrelated individuals served as controls.

We reported one *LRP5* variant (rs724159825) and three *PKD1* variants (rs724159824; rs724159822; rs724159823) described in this manuscript to the public dbSNP database.

Immunofluorescence and qPCR

Subsequently, immunofluorescence studies, luciferase activity assays and qPCR experiments with wild-type (WT) and four mutant *LRP5* constructs were conducted. Transfected HeLa cells were stained in order to elucidate the co-localization of LRP5 to the endoplasmic reticulum, Golgi apparatus and the plasma membrane (see Supplementary Information).

Luciferase activity assay and real-time-PCR

Wnt signaling activity was assessed using the Signal Reporter TCF/LEF Assay Kit (Qiagen, Hilden, Germany) after transfecting CHO or HEK293 cells with WT or mutant constructs and addition of hWnt3a (R&D Systems, Abingdon, UK).

Expression levels of Wnt target genes were assessed in Wnt3a-activated and non-activated transfected HEK293 cells by real-time-PCR.

RESULTS

A subset of 29 ADPKD patients had genotypic prescreening. Molecular diagnostics was performed for *PKD1*, *PKD2* and *PKHD1* (Chr.6p12.2; NG_008753.1) in adults. Additional analysis of *HNF1 β* (Chr.17q12; NG_013019.1) was performed in adolescents when genotype screening of *PKD1*, *PKD2* and *PKHD1* were negative. No point mutations, CNV or large deletions were identified and all 29 affected individuals were designated as being unlinked. A group of 50 patients had a clinical diagnosis of ADPKD with a symptomatic polycystic liver. Variants for PCLD in *PRKCSH* (Chr.19p13.2; NG_009300.1) and *SEC63* (Chr.6q21; NG_008270.1) affecting protein function were excluded, but the PKD genotype was unknown in this group. In this

heterogeneous cohort of 79 ADPKD patients, we identified four *LRP5* variants by Sanger sequencing (Table 1). Both unique *LRP5* variants were detected in the subgroup of ADPKD with a severe polycystic liver. Here, we present the data of three adult-onset ADPKD patients and one adolescent ADPKD patient (Figure 1 and Supplementary Figures S1–S3).

Family A

The proband (109) presented to us with a symptomatic polycystic liver and renal cysts of various sizes at 51 years of age (Table 1). She was clinically diagnosed as ADPKD. Mutational screening of *PRKCSH* and *SEC63* yielded no variants causing hepatic and renal cystogenesis. She was from Moroccan ancestry and her ancestors did not have renal disease suggestive for ADPKD. During the first pregnancy of her oldest daughter (202), polycystic kidneys and several small hepatic cysts were detected by abdominal ultrasonography. Renal failure was absent and mild hypertension was under control by use of an AT2-receptor antagonist. Both patients fulfilled the unified Ravine criteria for ADPKD.¹⁴

By *LRP5* variant analysis, we identified a unique missense variant *c.1680G>T*; (p.(Trp560Cys); rs377144001) in both Moroccan patients (109 and 202). This *LRP5* variant is not detected in genome-wide sequence data such as 1000 Genomes Project, and ~2000 in-house exome sequencing data from patients of European ancestry. In addition, *LRP5 c.1680G>T* is neither detected in 4400 African-American exome sequencing cohort from the National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project (ESP). This variant was recently identified once in an ESP European-American cohort with a total allele frequency of 1/12 988 (rs377144001, dbSNP v.138). The variant *LRP5 c.1680G>T* was not present among 525 tested Moroccan DNAs of unrelated individuals.

In silico analysis predicts this variant to be pathogenic and alters a conserved LRP5 amino acid (Table 2). Homology modeling indicated that this missense variant affects one of the tryptophans that are important for the core structure of this domain. Multiple hydrophobic interactions and a hydrogen bond will be lost by the tryptophane amino acid change into cysteine. This variant is highly likely to change the secondary and tertiary structure of the protein, and to disturb the function of the second WD40 domain function.

Variants in the genes *PKD2*, *PKHD1*, *PRKCSH* and *SEC63* affecting the protein function were absent, but molecular diagnostics of *PKD1* revealed two unique variants. Both *PKD1* variants, *c.1281_1283delGGC*; p.(Ala428del) (rs724159824) in exon 6 and *c.3133G>C*; p.(Val1045Leu) (rs724159822) in exon 13, were present in the proband (109). The p.(Ala428del) had been transmitted to the 33-year-old affected daughter (202), while the 27-year-old healthy daughter (203) inherited p.(Val1045Leu). In addition, the 25-year-old

Table 1 Patient characteristics

Family	Subject	Baseline characteristics			At first presentation (diagnosis)			Treatment for polycystic kidneys Medical/ Surgical
		Age (years)	Sex	Age (years)	Creatinin ($\mu\text{mol/l}$)	ESRD		
A	109	56	F	51	155	Yes	Thiazide and AT2-receptor antagonist; 9-months octreotide Antihypertensive treatment	
	202	33	F	24	79	No		
B	101	60	M	55	80	No	Antihypertensive treatment	
C	102	18	F	14	64	No	—	
D	101	51	F	43	114	Yes	Antihypertensive treatment; kidney transplantation	




Figure 1 Clinical and genetic data of ADPKD family A. **(a)** Pedigree of family A present two affected individuals, proband 109 and daughter 202. Affected individuals indicate those with confirmed ADPKD on CT scanning or abdominal ultrasound according to the Ravine criteria. **(b)** CT scanning in proband 109 presented a severe polycystic liver in segments 2, 3 and 8 and the kidney sizes were craniocaudal 19 cm (left) and 21 cm (right) in diameter. Abdominal ultrasonography in patient 202 assessed polycystic kidneys (white arrows) and multiple small hepatic cysts (dotted white arrows). **(c)** *PKD1* c.1281_1283delGGC and *PKD1* c.3133G>C were detected in the proband. Both *PKD1* variants are located in low evolutionary conserved regions in contrast to *LRP5* c.1680G>T. **(d)** The in-frame *PKD1* deletion is located on an extracellular C-type lectin domain at the end of a loop close to a double helix structure. The alanine deletion shortens the strand, but there is no destabilization of the domain which is closely located to a rigid double helix structure with many hydrogen bonds. Missense variant *PKD1* p.(Val1045Leu) is located on the fifth tandem PKD domain without a difference in charge between WT and mutant protein. **(e)** Confocal imaging studies in transiently transfected HeLa cells identified co-localization of LRP5 in the endoplasmic reticulum. There were no differences between LRP5 localization compared with the WT *LRP5* construct for all 4 *LRP5* variants.

healthy daughter (204) harbors also p.(Val1045Leu), but in a homozygous state (*PKD1* c.3133G>C homozygous). Both *PKD1* variants are unreported in the literature (unclassified variants), online and in-house databases and are localized in evolutionarily moderately low conserved domains.

The *PKD1* missense variant p.(Val1045Leu) may be a benign variant, as this variant had been transmitted to the unaffected daughter (203). The consequence of this *PKD1* variant is currently unclear, but non-penetrance or late-onset of ADPKD may play a role. The contributing effect of p.(Ala428del) is unclear, but homology modeling suggests that the nascent residues surrounding codon 248 are not conserved and that the C-type lectin domain is not pathogenic altered. It is well conceivable that the identified changes in this patient may exhibit their full pathogenic effect in concert.

Family B

A 57-year-old Dutch male came to our attention because of uncontrolled hypertension. Extensive clinical and radiological

examination demonstrated large, complicated (multilocular) renal cysts (Supplementary Figure S1).

There was no family history for polycystic diseases, liver or renal disease. Therefore, no consent was retrieved for phenotype and genotype screening in family members. *PKD1* and *PKD2* variants were absent in the proband and Sanger sequencing of the *LRP5* gene identified c.3107G>A; p.(Arg1036Gln; rs61889560). This variant reported an incidence of 0.001–0.005 (1/245) in public databases. The missense variant is located at the fourth WD40 and may lead to a less stabilized domain owing to loss of hydrogen and ion binding.

Family C

A 14-year-old female (102) was diagnosed with two large, symptomatic cysts with a diameter of 4.5 cm each and a small (‘intrapolar’) cyst was present in the left kidney with a normal right kidney (Supplementary Figure S2). Creatinine levels remained between 61 and 71 μmol/l within the normal range (50–90 μmol/l) during 4 years of follow-up. Her blood pressure was 130/70 mm Hg and regularly

Table 2 LRP5 variants in ADPKD patients

Family	Ethnicity	Position (GRCh37; hg19)	Variant (c.DNA; NM_002335.2)	Exon (NG_015835.1)	Predicted effect on protein	Polyphen2 (Class; score)	Mutpred	SIFT (Class; score)	Align GVGD	PhyloP	Grantham score	Frequency in controls ^a (EVS)
A	Moroccan	g.68171046	c.1680G>T	8	p.(Trp560Cys)	Probably damaging (1.00)	0.770	Deleterious (0.00)	Class C65 (GV:0.00-GD:214.36)	5.54	215	1/12 988
B	Dutch	g.68191036	c.3107G>A	14	p.(Arg1036Gln)	Possibly damaging (0.658)	0.785	Tolerated (0.06)	Class CO (GV:28.82-GD:19.90)	1.74	42	1/245
C	Dutch	g.68192736	c.3403C>T	15	p.(Arg1135Cys)	Probably damaging (1.00)	0.586	Deleterious (0.00)	Class C65 (GV:0.00-GD:179.53)	4.00	180	1/1299
D	Dutch	g.68193486	c.3468G>C	16	p.(Gln1156His)	Probably damaging (1.00)	0.702	Deleterious (0.00)	Class C15 (GV:0.00-GD:24.08)	3.76	24	—

^aAllele frequency.

monitored at home. Family history was negative for ADPKD, autosomal recessive polycystic kidney disease and PCLD or other genomic disorders, but her mother was diagnosed at the age of 30 with nephrotic syndrome of unknown cause. Both parents were screened and there were no structural renal abnormalities on ultrasonography.

Molecular diagnostics showed no evidence for the diagnosis of ADPKD or autosomal recessive polycystic kidney disease by analyses of the *PKD1*, *PKD2*, *PKHD1* and *HNF1β* gene. We identified the *LRP5* variant c.3403C>T; p.(Arg1135Cys; rs143396225). This variant is reported with a frequency of 1/1300 in the European American ESP cohort from the NHLBI, and absent in the 1000 Genomes Project dataset and ~2000 DNA exomes sequenced in-house. *In silico* analyses predicted *LRP5* c.3403C>T to be disease-associated with pathogenic effects for the protein function (Table 2). Homology modeling showed that the arginine is located at the fourth WD40 domain. The p.(Arg1135Cys) variant results in a change of a hydrophilic molecule to an apolar hydrophobic amino acid which may contribute to a destabilized WD40 domain. The loss of ionic interactions is likely to affect the function of the protein domain.

Family D

Bilateral enlarged kidneys containing multiple fluid-filled cysts were an accidental finding on ultrasonography in the proband (101) at the age of 43 (Supplementary Figure S3). Her blood pressure was under control (128/70 mm Hg) with an antihypertensive ACE-inhibitor and she used antacid medication. Eight years after identification of polycystic kidneys, the 51-year-old patient received renal transplant from a living unrelated donor.

Family history for polycystic or renal diseases was unremarkable. No *PRKCSH* or *SEC63* variants affecting the protein function were present, but *PKD* screening revealed two *PKD1* variants; c.8293C>T; p.(R2765C) (rs144979397) on exon 23 and *PKD1* c.11554delC; p.(L3852Wfs*93) (rs724159823) on exon 42. The mother also harbors the *PKD1* missense variant p.(R2765C), which is predicted to be likely hypomorphic.^{15–17} Frameshift variant *PKD1* c.11554delC is a recently reported variant with a clear pathogenic character.¹⁶ *PKD1* analysis in genomic DNA from the father was unavailable.

Sequence analysis of the *LRP5* gene yielded a unique *LRP5* c.3468G>C; p.(Gln1156His) (rs724159825) in the proband which was absent in the DNA from both parents. The *LRP5* variant p.(Gln1156His) was absent in dbSNP and all aforementioned online and in-house exome sequence datasets. This missense variant was predicted to be damaging and the amino acid is located between blades 5 and 6 of the fourth β-propeller domain. Glutamine may interact by hydrogen bonds with adjacent arginine, but shows hydrophobic features at this position. Histidine contains an imidazole functional group which stereometrically changes the position. The major effect of this missense variant is the change in electrostatic charge which may result in disturbed interactions at the surface of the protein domain.

Functional studies

Confocal imaging studies identified co-localization of *LRP5* in the endoplasmic reticulum, but no differences were identified between *LRP5* localization compared with the WT *LRP5* construct for all four *LRP5* variants (Figure 1).

Luciferase activity assays of variant *LRP5* compared with WT *LRP5* constructs were conducted to estimate Wnt signaling defects. Addition of ligand Wnt3a reduced Wnt signaling activity in *LRP5* variants p.(Trp560Cys), p.(Arg1036Gln) and p.(Gln1156His) (Figure 2). Wnt signaling activation showed an increasing tendency for *AXIN2* and *LEF1* gene expression (Supplementary Figures). *LRP5* variant




Figure 2 *LRP5* variants present reduced activation of canonical Wnt signaling. **(a)** Canonical Wnt signaling activity was analyzed by firefly luciferase activity and normalized to renilla luciferase activity without (white bar) and with (grey bar) addition of 250 ng/ml Wnt3a. *LRP5* constructs showed a significant increase in Wnt signaling activity compared with the empty vector. *LRP5* variants p.(Trp560Cys), p.(Arg1036Gln) and p.(Gln1156His) presented a decreased Wnt3a-induced signal activity (* $P < 0.05$; ** $P < 0.01$). **(b)** All *LRP5* variants indicated only concordantly increased *AXIN2* expression levels by Wnt3a activation. **(c)** *LEF1* and others showed slightly increased gene expression. Significant increased *AXIN1* and *LEF1* expression by Wnt3a activation was present in *LRP5* variant p.(Trp560Cys) compared with *LRP5* WT (* $P < 0.05$). The y-axis presents the relative gene expression level.

p.(Trp560Cys) compared with *LRP5* WT presented significant increased *AXIN1* and *LEF1* expression by Wnt3a activation.

DISCUSSION

The data presented here suggest a role of *LRP5* in ADPKD. We discovered two unique and two rare *LRP5* variants in ADPKD patients regardless of family history or presence of *PKD* mutations. The association of *LRP5* variants with hepatic cystogenesis was identified in an extended PCLD pedigree.¹³ The fact that polycystic livers are present in up to 94% of ADPKD patients² prompted us to investigate the possible pathogenic role of *LRP5* variants in ADPKD patients. There are a number of functional and animal studies that support the thinking that *LRP5* variants may contribute to hepatic and renal cystogenesis.

LRP5 is a single transmembrane co-receptor involved in the canonical Wnt signaling pathway that orchestrates mammalian organogenesis. Northern blotting studies indicate that *LRP5* is strongly expressed in both liver and kidneys.¹⁸ In addition, there is abundant *LRP5* expression in convoluted tubules of human and mouse kidneys.¹⁹ Canonical Wnt signaling is established by binding of a Wnt ligand to a cognate Frizzled receptor in the presence of *LRP5*. The role of canonical Wnt signaling in ADPKD has been an area of research.^{20–25}

Increased canonical Wnt signaling^{20–22} and diminished signal activation or stable β -catenin^{23–25} that lead to an opposite effect of planar cell polarity/noncanonical signaling have been reported in different ADPKD mouse models. These data suggest renal cystogenesis is initiated by imbalance between canonical and planar cell polarity/non-canonical signaling.²⁶ Indeed, polycystins modulate Wnt activity and disruption of either pathway may lead to polycystic kidney disease.^{20,21} During the late stage of nephron maturation, polycystins are required for terminal differentiation of epithelial cells.²⁷ This led to the model that put the canonical/ β -catenin pathway as one of the downstream effectors for ADPKD.²⁸

A targeted knock-out *LRP5* mouse develops hepatobiliary abnormalities without specified hepatic nor renal morphology,²⁴ although it is known that *LRP5* models have limited severity of Wnt disease phenotype compared with the almost identical *LRP6* gene.²⁹

The *LRP6* knock-out mouse model is lethal, in view of severe developmental defects that affect skeleton, retina and ureter (E8.5). At E18.5, macroscopic small cystic kidneys are visible, suggesting a PKD phenotype.²⁴ These findings support the notion that Wnt signaling is pivotal during early kidney development while polycystins appear to be critical during final stages of renal tubulogenesis.²⁸

This paper provides evidence that the discovered variants affect *LRP5* function. Luciferase activity assays of four *LRP5* constructs decrease Wnt3a-induced signal activation across various cell lines (Figure 2).¹³ In addition, the expression of *AXIN2*, a Wnt signaling gene is enhanced in the presence of three *LRP5* mutants (Supplementary Figure S5). This suggests that there is constitutive activation of the Wnt signaling as a result of these *LRP5* variants.

Loss or gain of function of genes involved in Wnt signaling may lead to an imbalance between canonical and noncanonical signaling events.³⁰ There is evidence that key players of Wnt signaling modulate the renal disease severity in ADPKD by antagonizing canonical Wnt signaling.^{5,6} Three single nucleotide polymorphisms in dickkopf Wnt signaling pathway inhibitor 3 (*DKK3*) downregulate canonical Wnt signaling similar to our data for *LRP5*.⁵ In addition, *HNF-1 β* which orchestrates Wnt signaling may aggravate congenital renal cystogenesis in mice and human autosomal recessive polycystic kidney disease and ADPKD.^{6,17} Failure of canonical Wnt signaling homeostasis will result in activated noncanonical signaling. It is likely that other genes or modifier genes in the Wnt signaling pathway are linked to hepatic and renal cystogenesis.²⁰

Multiple *PKD* variants may cause early and more severe renal disease in ADPKD.⁶ Although the pathogenic character of both *PKD1* variants in family A remains unclear, we surmise that the resulting in-frame deletion of an alanine amino acid neighboring another alanine does not significantly affect the protein domain structure. A *PKD1* missense variant p.(Val1045Met) (*c.3133G>A*) in the fifth PKD domain has been predicted to be likely hypomorphic.³¹ At the similar sequence position, we detected *PKD1 c.3133G>C* leading to a hydrophobic amino acid change. Leucine and methionine are different regarding presence of a methyl group in leucine and a sulfide molecule in methionine, which are both larger components compared with amino acid valine.

The case is different for the *PKD1* variants identified in proband 101 from family D. *PKD1* c.8293C>T; p.(Arg2765Cys) is present in an unaffected parent, but also is probably hypomorphic and weakly conserved.^{15,32} The second *PKD1* variant, c.11554delC; p.(Leu3852Trpfs*93), is detected by next-generation sequencing and probably causative for the ADPKD phenotype.¹⁶ This family had a negative history for ADPKD that suggests a *de novo* onset of the *PKD1* gene variant which has been described before.¹² In order to detect the additional mutational effect of a *LRP5* variant to the *PKD1* c.1154delC, investigation of the severity of clinical ADPKD phenotype and subsequent functional studies are required.

Previous studies provided evidence that the type of *PKD1* variant correlates strongly with renal survival. Carriers of a truncating *PKD1* variant have an earlier age at onset of end-stage renal disease which supports the concept of a genotype–phenotype correlation in ADPKD.³³

In conclusion, several *in vitro* and *in vivo* studies suggest involvement of aberrant Wnt signaling and unregulated β -catenin levels contribute to renal cystogenesis.^{23,24} Our findings are in line with the hypothesis that genes encoding Wnt/ β -catenin signaling partners may be candidate loci for cystic disorders.^{13,20} We postulate that *LRP5* variants may render ADPKD patients more susceptible to the development of polycystic liver although further studies are needed to validate our findings.

CONFLICT OF INTEREST

WRC is supported by a grant of the Institute for Genetic and Metabolic Disease (IGMD) of the Radboud university medical center and by a grant from the Dutch foundation of digestive diseases WO10-50 (MLDS). The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank our patients and their families for their participation and providing samples. We appreciate the input of the Genomic Disorders Group from the Department of Human Genetics, Radboud university medical center. We thank Mrs Irene Otte-Höller, Department of Pathology; Mr Ing. Huib Croes, Department of Cell Biology, Radboud university medical center for advice and expertise. Dr ADM Stork, internal medicine (St Anna Ziekenhuis Geldrop) and Dr A Bökenkamp, pediatric nephrologist (VUmc Amsterdam) for sharing clinical information. This work was funded by the Institute of Genetic and Metabolic Diseases (IGMD) of the Radboud university medical center and by a grant from the Dutch foundation of digestive diseases (MLDS; WO10-50). These study sponsors were not involved in study design or in collection, analysis, and interpretation of data.

- 1 Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. *Lancet* 2007; **369**: 1287–1301.
- 2 Bae KT, Zhu F, Chapman AB *et al*: Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. *Clin J Am Soc Nephrol* 2006; **1**: 64–69.
- 3 Luciano RL, Dahl NK: Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. *Nephrol Dial Transplant* 2014; **29**: 247–254.
- 4 Torra R, Darnell A, Estivill X *et al*: Interfamilial and intrafamilial variability of clinical expression in ADPKD. *Contrib Nephrol* 1995; **115**: 97–101.
- 5 Liu M, Shi S, Senthilnathan S, Yu *et al*: Genetic variation of DKK3 may modify renal disease severity in ADPKD. *J Am Soc Nephrol* 2010; **21**: 1510–1520.

- 6 Bergmann C, von Bothmer J, Ortiz Bruchle N *et al*: Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. *J Am Soc Nephrol* 2011; **22**: 2047–2056.
- 7 Rossetti S, Harris PC: Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. *J Am Soc Nephrol* 2007; **18**: 1374–1380.
- 8 The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. *Cell* 1994; **77**: 881–894.
- 9 Mochizuki T, Wu G, Hayashi T *et al*: PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. *Science* 1996; **272**: 1339–1342.
- 10 Peters DJ, Sandkuijl LA: Genetic heterogeneity of polycystic kidney disease in Europe. *Contrib Nephrol* 1992; **97**: 128–139.
- 11 Rossetti S, Consugar MB, Chapman AB *et al*: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2007; **18**: 2143–2160.
- 12 Reed B, McFann K, Kimberling WJ *et al*: Presence of *de novo* mutations in autosomal dominant polycystic kidney disease patients without family history. *Am J Kidney Dis* 2008; **52**: 1042–1050.
- 13 Cossen WR, Te Morsche RH, Hoischen A *et al*: Whole-exome sequencing reveals *LRP5* mutations and canonical Wnt signaling associated with hepatic cystogenesis. *Proc Natl Acad Sci USA* 2014; **111**: 5343–5348.
- 14 Pei Y, Obaji J, Dupuis A *et al*: Unified criteria for ultrasonographic diagnosis of ADPKD. *J Am Soc Nephrol* 2009; **20**: 205–212.
- 15 Gout AM, Martin NC, Brown AF: PKDB: Polycystic Kidney Disease Mutation Database—a gene variant database for autosomal dominant polycystic kidney disease. *Hum Mutat* 2007; **28**: 654–659.
- 16 Rossetti S, Hopp K, Sikkink RA *et al*: Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. *J Am Soc Nephrol* 2012; **23**: 915–933.
- 17 Hiesberger T, Bai Y, Shao X *et al*: Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice. *J Clin Invest* 2004; **113**: 814–825.
- 18 Hey PJ, Twells RC, Phillips MS *et al*: Cloning of a novel member of the low-density lipoprotein receptor family. *Gene* 1998; **216**: 103–111.
- 19 Figueroa DJ, Hess JF, Ky B *et al*: Expression of the type I diabetes-associated gene *LRP5* in macrophages, vitamin A system cells, and the Islets of Langerhans suggests multiple potential roles in diabetes. *J Histochem Cytochem* 2000; **48**: 1357–1368.
- 20 Saadi-Kheddouci S, Berrebi D, Romagnolo B *et al*: Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. *Oncogene* 2001; **20**: 5972–5981.
- 21 Qian CN, Knol J, Igarashi P *et al*: Cystic renal neoplasia following conditional inactivation of *apc* in mouse renal tubular epithelium. *J Biol Chem* 2005; **280**: 3938–3945.
- 22 Happe H, Leonhard WN, van der Wal A *et al*: Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. *Hum Mol Genet* 2009; **18**: 2532–2542.
- 23 Miller MM, Iglesias DM, Zhang Z *et al*: T-cell factor/beta-catenin activity is suppressed in two different models of autosomal dominant polycystic kidney disease. *Kidney Int* 2011; **80**: 146–153.
- 24 Pinson KI, Brennan J, Monkley S *et al*: An LDL-receptor-related protein mediates Wnt signalling in mice. *Nature* 2000; **407**: 535–538.
- 25 Marose TD, Merkel CE, McMahon AP *et al*: Beta-catenin is necessary to keep cells of ureteric bud/Wolffian duct epithelium in a precursor state. *Dev Biol* 2008; **314**: 112–126.
- 26 Lancaster MA, Gleeson JG: Cystic kidney disease: the role of Wnt signaling. *Trends Mol Med* 2010; **16**: 349–360.
- 27 Lu W, Peissel B, Babakanlou H *et al*: Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkd1 mutation. *Nat Genet* 1997; **17**: 179–181.
- 28 Kim E, Arnould T, Sellin LK *et al*: The polycystic kidney disease 1 gene product modulates Wnt signaling. *J Biol Chem* 1999; **274**: 4947–4953.
- 29 Fujino T, Asaba H, Kang MJ *et al*: Low-density lipoprotein receptor-related protein 5 (*LRP5*) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. *Proc Natl Acad Sci USA* 2003; **100**: 229–234.
- 30 Simons M, Gloy J, Ganner A *et al*: Inversin, the gene product mutated in nephronphthisis type II, functions as a molecular switch between Wnt signaling pathways. *Nat Genet* 2005; **37**: 537–543.
- 31 Vujic M, Heyer CM, Ars E *et al*: Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. *J Am Soc Nephrol* 2010; **21**: 1097–1102.
- 32 Rossetti S, Kubly VJ, Consugar MB *et al*: Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. *Kidney Int* 2009; **75**: 848–855.
- 33 Cornec-Le Gall E, Audrezet MP, Chen JM *et al*: Type of PKD1 mutation influences renal outcome in ADPKD. *J Am Soc Nephrol* 2013; **24**: 1006–1013.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)